<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071589</url>
  </required_header>
  <id_info>
    <org_study_id>2006-006159-11</org_study_id>
    <secondary_id>CIM/06/300/04</secondary_id>
    <nct_id>NCT02071589</nct_id>
  </id_info>
  <brief_title>Bioavailability Of A Single Dose Of Nifedipine Oral Solution Compared To Adalat Capsules In Healthy Female Volunteers</brief_title>
  <acronym>NIFEPAR_PK1</acronym>
  <official_title>Crossover Randomised Bioavailability Clinical Study Of A Single Dose Of Nifedipine Oral Solution From Laboratorio Reig Jofre S.A. Compared To Adalat(R) Capsules In Healthy Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reig Jofre Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reig Jofre Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, crossover, randomised, single dose, relative bioavailability clinical trial of a new
      oral solution of nifedipine compared to Adalat soft gelatine capsules in healthy female
      volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was designed to compare the bioavailability of nifedipine new formulation specially
      designed to be used in pre-term labour management instead of anti-hypertensive therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC 0-24h)</measure>
    <time_frame>pre-dose and +10', +20', +30', +45', +1h, +1h15', +1h30', +2h, +3h, +5h, +7h, +9h, +12h y +24h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal plasmatic concentrations, Cmax</measure>
    <time_frame>pre-dose and +10', +20', +30', +45', +1h, +1h15', +1h30', +2h, +3h, +5h, +7h, +9h, +12h y +24h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximal plasmatic concentrations, Tmax</measure>
    <time_frame>pre-dose and +10', +20', +30', +45', +1h, +1h15', +1h30', +2h, +3h, +5h, +7h, +9h, +12h y +24h post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Nifedipine oral solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nifedipine 5 mg/mL oral solution, 6 mL (30 mg of Nifedipine) at single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine soft gelatine capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nifedipine soft gelatine capsules x3 (total 30 mg Nifedipine) at a single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine soft gelatine capsules</intervention_name>
    <description>3 Adalat capsules of 10 mg each one</description>
    <arm_group_label>Nifedipine soft gelatine capsules</arm_group_label>
    <other_name>Adalat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine oral solution</intervention_name>
    <description>6 mL of Nife Par solution</description>
    <arm_group_label>Nifedipine oral solution</arm_group_label>
    <other_name>Nife-Par</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18 to 45.

          -  Body weight within the normal range (Quetelet index between 19 and 26) expressed as
             weight (kg) / height (m2) .

          -  Medical history , physical examination within normal appliances .

          -  No evidence of significant organic or psychiatric disease based on history, physical
             examination and laboratory tests .

          -  Laboratory tests (hematology and biochemistry) within the normal range , according to
             normal reference values of the Biochemistry laboratory of Hospital de la Santa Creu i
             Sant Pau. Variations may be allowed based on clinical judgment of the Centre d'
             Investigacio Medicament (CIM ) .

          -  Vital signs: blood pressure (Systolic Blood Pressure (SBP) &gt; 90 &lt;140 mm Hg / Diastolic
             Blood Pressure (DBP) &gt; 50 &lt;90 mm Hg ), heart rate (&gt; 50 &lt;90 ) , temperature and ECG
             record within normal range.

          -  Not having participated in another clinical trial during the previous three months at
             the beginning of the current study .

          -  Not having donated blood in the previous four weeks.

          -  Free acceptance to participate in the trial. Written informed consent signed.

          -  Use of effective contraception different from oral contraceptives.

        Exclusion Criteria:

          -  Previous history of alcohol or drug use or abuse during the previous month to the
             selection process.

          -  High consumption of stimulant beverages (&gt; 5 coffee, tea, cola drinks daily).

          -  Previous history of allergy, drug hypersensitivity or idiosyncrasy.

          -  Taking any medication in the 4 weeks preceding the trial, including non-prescription
             medicines and herbal remedies.

          -  Positive serology for hepatitis B, C or HIV.

          -  History or clinical evidence of cardiovascular disease, respiratory, renal, hepatic,
             endocrine, gastrointestinal, hematological, neurological or other chronic diseases.

          -  Having had surgery during the previous 6 months.

          -  Having donated blood in the month before the study began.

          -  Smokers.

          -  Positive pregnancy test at any monitoring during the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa M Antonijoan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIM Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIM Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>February 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <last_update_submitted>February 22, 2014</last_update_submitted>
  <last_update_submitted_qc>February 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

